Figure 1

Expression of FGF13 mRNAs is upregulated in HeLa cisR and S180 cisR cells.

(A). Phase contrast micrographs showing HeLa S and HeLa cisR cells cultured for 3 days in the absence or presence of cisplatin (10 μg/ml). (B). Effects of cisplatin and carboplatin on proliferation measured by MTT-assay. HeLa cisR, open squares; HeLa S, filled circles. ***, p < 0.001. (C). Levels of FGF13 mRNA expression detected by quantitative RT-PCR presented as fold increases over control. ***, p < 0.001. (D). FGF13 mRNA expression presented as fold changes from HeLa S cells. Five intermediate cell lines (#1 to #5, adapted to 0.42, 0.84, 2.0, 6.0 and 8.0 μg/ml cisplatin) were collected during the process of establishing the HeLa cisR. **, p < 0.01; *, p < 0.05. (E). FACS analysis of FGF13 expression. Solid line, treated with anti-FGF13 antibody; dotted line, without anti-FGF13 antibody. (F). Immunofluorescence analysis of FGF13 in HeLa S cells transiently transfected with FGF13-expression vector (a) or mock vector (c). Nuclei were counterstained with propidium iodide (b and d). (G). Effects of cisplatin on the proliferation. S180 cisR, open squares; S180 cells, filled circles. ***, p < 0.001. (H). FGF13 mRNA expression in S180 cisR. ***, p < 0.001.